Progressive multifocal leukoencephalopathy and granule cell neuronopathy with novel mutation flanking VP1 C-terminus in natalizumab-extended interval dosing
Open Access
- 1 May 2020
- journal article
- editorial
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology Neuroimmunology & Neuroinflammation
Abstract
Reactivation of a dormant infection with the John Cunningham virus (JCV) can lead to the rare neurologic disorders progressive multifocal leukoencephalopathy (PML) and granule cell neuronopathy (GCN), a cerebellar syndrome with progressing cerebellar atrophy.(1)Here, we present a case of infratentorial PML with concomitant GCN in extended interval dosing (EID) of natalizumab associated with a novel mutation at 7th position after the C-terminus of viral capsid protein VP1 in addition to the common noncoding regulatory region (NCRR) mutation.Keywords
This publication has 7 references indexed in Scilit:
- Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosingNeurology, 2019
- The spectrum of progressive multifocal leukoencephalopathy: a practical approachEuropean Journal of Neurology, 2019
- Understanding Progressive Multifocal Leukoencephalopathy Risk in Multiple Sclerosis Patients Treated with immunomodulatory Therapies: A Bird's eye viewFrontiers in Immunology, 2018
- Heterogeneous imaging characteristics of JC virus granule cell neuronopathy (GCN): a case series and review of the literatureZeitschrift für Neurologie, 2014
- JCV GCN in a natalizumab-treated MS patient is associated with mutations of the VP1 capsid geneNeurology, 2014
- Multiplex qPCR assay for ultra sensitive detection of JCV DNA with simultaneous identification of genotypes that discriminates non-virulent from virulent variantsJournal of Clinical Virology, 2013
- Sequencing and Analysis of JC Virus DNA From Natalizumab-Treated PML PatientsThe Journal of Infectious Diseases, 2011